Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Raw Materials (2022)

Amylyx Pharmaceuticals has reported Raw Materials over the past 1 years, most recently at $7.2 million for Q4 2022.

  • Quarterly results put Raw Materials at $7.2 million for Q4 2022, changed N/A from a year ago — trailing twelve months through Dec 2022 was $7.2 million (changed N/A YoY), and the annual figure for FY2022 was $7.2 million, changed.
  • Raw Materials for Q4 2022 was $7.2 million at Amylyx Pharmaceuticals, up from $408000.0 in the prior quarter.
  • Over the last five years, Raw Materials for AMLX hit a ceiling of $7.2 million in Q4 2022 and a floor of $408000.0 in Q3 2022.